{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:25:18Z","timestamp":1790378718907,"version":"4.1.0"},"reference-count":237,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Hepatic steatosis, the hallmark of metabolic dysfunction-associated steatotic liver disease (MASLD), is closely associated with elevated plasma and intrahepatic triglyceride (TG) levels, often driven by insulin resistance, atherogenic dyslipidemia, and metabolic syndrome. Growing evidence suggests that triglyceride-lowering therapies may not only improve systemic lipid profiles but also directly impact hepatic fat accumulation and associated inflammation and fibrosis. This review explores current and emerging TG-lowering therapies, including fibrates, omega-3 fatty acids, pemafibrate, and novel agents such as pegozafermin (an FGF21 analog), and APOC3 and angiopoietin-like protein 3 (ANGPTL3) inhibitors, in the context of hepatic steatosis and MASLD. We discuss the mechanistic rationale behind TG-lowering as a therapeutic strategy, summarize key preclinical and clinical trial findings, and evaluate their effects on liver fat content, liver enzymes, fibrosis markers, and histologic outcomes. While several agents demonstrate promise in reducing intrahepatic fat deposition and improving liver-related outcomes, further large-scale studies are required to establish their long-term efficacy and safety, and potential for disease modification in MASLD\/metabolic dysfunction-associated steatohepatitis (MASH). Triglyceride-targeted therapies may offer a valuable adjunct or complementary approach to current treatment paradigms focused on weight loss, insulin sensitization, and antagonizing inflammation.<\/jats:p>","DOI":"10.3389\/fphar.2026.1789019","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:44:29Z","timestamp":1778564669000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives"],"prefix":"10.3389","volume":"17","author":[{"given":"Seyed Saeed","family":"Tamehri Zadeh","sequence":"first","affiliation":[{"name":"International Lipid Expert Panel (ILEP)","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[{"name":"Preventive Cardiology, CGH Medical Center","place":["Rock Falls, IL, United States"]},{"name":"Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[{"name":"Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]},{"name":"Faculty of Medicine, John Paul II Catholic University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12011","DOI":"10.1073\/pnas.0505714102","article-title":"Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal","volume":"102","author":"Abu-Elheiga","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","article-title":"Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia","volume":"78","author":"Ahmad","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e10446","DOI":"10.7759\/cureus.10446","article-title":"Pleiotropic effects of statins in the light of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"12","author":"Ahsan","year":"2020","journal-title":"Cureus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2021.1489","article-title":"Effect of marine omega-3 fatty acid and vitamin D supplementation on incident atrial fibrillation: a randomized clinical trial","volume":"325","author":"Albert","year":"2021","journal-title":"Jama"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur. Heart J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cphy.c170012","article-title":"Triglyceride metabolism in the liver","volume":"8","author":"Alves-Bezerra","year":"2017","journal-title":"Compr. Physiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clinthera.2022.12.008","article-title":"Inhibition of diacylglycerol acyltransferase 2 versus diacylglycerol acyltransferase 1: potential therapeutic implications of pharmacology","volume":"45","author":"Amin","year":"2023","journal-title":"Clin. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.trsl.2016.02.008","article-title":"Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy","volume":"173","author":"Annema","year":"2016","journal-title":"Transl. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort","volume":"73","author":"Anstee","year":"2020","journal-title":"J. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/hep.26717","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease","volume":"59","author":"Armstrong","year":"2014","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.beem.2005.07.004","article-title":"Human fat cell lipolysis: biochemistry, regulation and clinical role","volume":"19","author":"Arner","year":"2005","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","article-title":"ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Assessment","year":"2009","journal-title":"Jama"},{"key":"B15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","article-title":"Practical guidance for combination lipid-modifying therapy in high-and very-high-risk patients: a statement from a European Atherosclerosis Society Task Force","volume":"325","author":"Averna","year":"2021","journal-title":"Atherosclerosis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","article-title":"Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents","volume":"55","author":"Baass","year":"2009","journal-title":"Clin. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/joim.13016","article-title":"Familial chylomicronemia syndrome: an under\u2010recognized cause of severe hypertriglyceridaemia","volume":"287","author":"Baass","year":"2020","journal-title":"J. Inte. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3803\/EnM.2024.103","article-title":"No more NAFLD: the term is now MASLD","volume":"39","author":"Bae","year":"2024","journal-title":"Endocrinol. Metabol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.5114\/aoms\/141941","article-title":"PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021","volume":"17","author":"Banach","year":"2021","journal-title":"Archives Med. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12933-022-01684-5","article-title":"Personalized management of dyslipidemias in patients with diabetes\u2014it is time for a new approach (2022)","volume":"21","author":"Banach","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"B22","first-page":"1602","article-title":"The year in cardiovascular disease\u2013the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?","volume-title":"Arch. Med. Sci.: AMS","author":"Banach","year":"2023"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.5114\/aoms\/197331","article-title":"The prevention opportunities of retinopathy in diabetic patients\u2013position paper endorsed by the Polish Lipid Association","volume":"20","author":"Banach","year":"2024","journal-title":"Archives Med. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/MOL.0000000000000960","article-title":"Fibroblast growth factor 21: update on genetics and molecular biology","volume":"36","author":"Barros","year":"2025","journal-title":"Curr. Opin. Lipidol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2004168","DOI":"10.1002\/advs.202004168","article-title":"Mistranslation drives alterations in protein levels and the effects of a synonymous variant at the fibroblast growth factor 21 locus","volume":"8","author":"Bayoumi","year":"2021","journal-title":"Adv. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jacl.2013.04.001","article-title":"Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association","volume":"7","author":"Bays","year":"2013","journal-title":"J. Clin. Lipidol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of vupanorsen on non\u2013high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-025-01315-w","article-title":"ApoC-III as therapeutic target: is it primetime for clinical use?","volume":"27","author":"Biolo","year":"2025","journal-title":"Curr. Atheroscler. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1210\/jc.2018-01446","article-title":"Effects of pitavastatin on insulin sensitivity and liver fat: a randomized clinical trial","volume":"103","author":"Braun","year":"2018","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"B33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.atherosclerosis.2011.03.023","article-title":"Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study","volume":"217","author":"Brouwers","year":"2011","journal-title":"Atherosclerosis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.4014\/jmb.2307.07018","article-title":"Role of Dgat2 in glucose uptake and fatty acid metabolism in C2C12 skeletal Myotubes","volume":"33","author":"Bu","year":"2023","journal-title":"J. Microbiol. Biotechnol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/j.1365-2036.2006.02885.x","article-title":"Prolonged n\u20103 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non\u2010alcoholic fatty liver disease: a pilot study","volume":"23","author":"Capanni","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.2337\/dc22-2048","article-title":"High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold","volume":"46","author":"Castera","year":"2023","journal-title":"Diabetes Care"},{"key":"B38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.cmet.2005.04.002","article-title":"\u201cNew\u201d hepatic fat activates PPAR\u03b1 to maintain glucose, lipid, and cholesterol homeostasis","volume":"1","author":"Chakravarthy","year":"2005","journal-title":"Cell Metab."},{"key":"B39","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/MED.0000000000000857","article-title":"APOC3 siRNA and ASO therapy for dyslipidemia","volume":"31","author":"Chebli","year":"2024","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6358","DOI":"10.1073\/pnas.0931394100","article-title":"Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero","volume":"100","author":"Chirala","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B41","doi-asserted-by":"publisher","first-page":"22678","DOI":"10.1074\/jbc.M704213200","article-title":"Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance","volume":"282","author":"Choi","year":"2007","journal-title":"J. Biol. Chem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"A12594","DOI":"10.1161\/circ.142.suppl_3.12594","article-title":"Pharmacodynamic effect of aro-apoc3, an investigational hepatocyte-targeted rna interference therapeutic targeting apolipoprotein c3, in patients with hypertriglyceridemia and multifactorial chylomicronemia","volume":"142","author":"Clifton","year":"2020","journal-title":"Circulation"},{"key":"B43","doi-asserted-by":"publisher","first-page":"A10357","DOI":"10.1161\/circ.144.suppl_1.10357","article-title":"ARO-APOC3, an Investigational RNAi therapeutic, shows similar efficacy and safety in genetically confirmed FCS and non-FCS participants with severe hypertriglyceridemia","volume":"144","author":"Clifton","year":"2021","journal-title":"Circulation"},{"key":"B44","first-page":"842","volume-title":"Steatohepatitis: a tale of two \u201chits\u201d?","author":"Day","year":"1998"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1001\/jama.2019.17380","article-title":"Effect of vitamin D and omega-3 fatty acid supplementation on kidney function in patients with type 2 diabetes: a randomized clinical trial","volume":"322","author":"de Boer","year":"2019","journal-title":"Jama"},{"key":"B46","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s40265-021-01510-4","article-title":"Targeting AMPK by statins: a potential therapeutic approach","volume":"81","author":"Dehnavi","year":"2021","journal-title":"Drugs"},{"key":"B47","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/MCO.0b013e328042ba90","article-title":"Free fatty acids and insulin resistance","volume":"10","author":"Delarue","year":"2007","journal-title":"Curr. Opin. Clin. Nutr. Metabolic Care"},{"key":"B48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.tem.2018.03.013","article-title":"Beyond LDL: what role for PCSK9 in triglyceride-rich lipoprotein metabolism?","volume":"29","author":"Dijk","year":"2018","journal-title":"Trends Endocrinol. Metabolism"},{"key":"B50","first-page":"12","article-title":"PCSK9 administration ameliorates non alcoholic fatty disease in patients with heterozygous familial hyperlipidemia","volume":"9","author":"Dimakopoulou","year":"2018","journal-title":"Hell. J. Atheroscler."},{"key":"B51","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/s1262-3636(07)70061-7","article-title":"Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease","volume":"29","author":"Diraison","year":"2003","journal-title":"Diabetes Metabolism"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1053\/j.gastro.2006.02.006","article-title":"Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis","volume":"130","author":"Doege","year":"2006","journal-title":"Gastroenterology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Invest."},{"key":"B54","doi-asserted-by":"publisher","first-page":"429","DOI":"10.7555\/JBR.29.20150052","article-title":"PCSK9 and triglyceride-rich lipoprotein metabolism","volume":"29","author":"Druce","year":"2015","journal-title":"J. Biomed. Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00535-012-0533-z","article-title":"Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study","volume":"47","author":"Eguchi","year":"2012","journal-title":"J. Gastroenterol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease\u2010specific mortality in NAFLD after up to 33 years of follow\u2010up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"CD008623","DOI":"10.1002\/14651858.CD008623.pub2","article-title":"Statins for non\u2010alcoholic fatty liver disease and non\u2010alcoholic steatohepatitis","volume":"12","author":"Eslami","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"B58","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.23280","article-title":"Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications","volume":"51","author":"Fabbrini","year":"","journal-title":"Hepatology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1210\/jc.2009-2622","article-title":"Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease","volume":"95","author":"Fabbrini","year":"","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"B61","doi-asserted-by":"publisher","first-page":"101816","DOI":"10.1016\/j.clinre.2021.101816","article-title":"Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis","volume":"46","author":"Fatima","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"106179","DOI":"10.1016\/j.jff.2024.106179","article-title":"Effects of triglyceride and ethyl ester forms of EPA on hepatic lipid metabolism in mice with non-alcoholic fatty liver disease","volume":"116","author":"Feng","year":"2024","journal-title":"J. Funct. Foods"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1126\/science.1130773","article-title":"Caveolin-1 is essential for liver regeneration","volume":"313","author":"Fern\u00e1ndez","year":"2006","journal-title":"Science"},{"key":"B64","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","article-title":"A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease","volume":"40","author":"Fern\u00e1ndez-Miranda","year":"2008","journal-title":"Dig. Liver Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2010.01275.x","article-title":"Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP\u20101c","volume":"12","author":"Ferre","year":"2010","journal-title":"Diabetes, Obesity Metabolism"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100648","article-title":"New approaches to triglyceride reduction: is there any hope left?","volume":"18","author":"Filtz","year":"2024","journal-title":"Am. J. Prev. Cardiol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/HCO.0b013e3283043806","article-title":"Multiple actions of high-density lipoprotein","volume":"23","author":"Florentin","year":"2008","journal-title":"Curr. Opin. Cardiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/ajg.2010.299","article-title":"Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial","volume":"106","author":"Foster","year":"2011","journal-title":"J. Am. Coll. Gastroenterol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"8879227","DOI":"10.1155\/2021\/8879227","article-title":"Associations among dietary omega\u20103 polyunsaturated fatty acids, the gut microbiota, and intestinal immunity","volume":"2021","author":"Fu","year":"2021","journal-title":"Mediat. Inflammat."},{"key":"B69","doi-asserted-by":"publisher","first-page":"100446","DOI":"10.1016\/j.xcrm.2021.100446","article-title":"Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia","volume":"2","author":"Fukami","year":"2021","journal-title":"Cell Rep. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/ueg2.12534","article-title":"Fibroblast growth factor 21 is a hepatokine involved in MASLD progression","volume":"12","author":"Gallego\u2010Dur\u00e1n","year":"2024","journal-title":"United Eur. Gastroenterol. J."},{"key":"B71","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur. Heart J."},{"key":"B73","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/0003319709351258","article-title":"The role of polymorphisms within paraoxonases (192 Gln\/Arg in PON1 and 311Ser\/Cys in PON2) in the modulation of cardiovascular risk: a pilot study","volume":"61","author":"Gluba","year":"2010","journal-title":"Angiology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejim.2023.10.013","article-title":"Residual cardiovascular risk: When should we treat it?","volume":"120","author":"Gomez-Delgado","year":"2023","journal-title":"Eur. J. Intern. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s11883-023-01140-z","article-title":"Updates in drug treatment of severe hypertriglyceridemia","volume":"25","author":"Gouni-Berthold","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"key":"B78","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"G1281","DOI":"10.1152\/ajpgi.00074.2008","article-title":"Gene expression in human NAFLD","volume":"294","author":"Greco","year":"2008","journal-title":"Am. J. Physiology-Gastrointestinal Liver Physiology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n\u2212 3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"key":"B82","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1042\/CS20140832","article-title":"Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk","volume":"128","author":"Guardiola","year":"2015","journal-title":"Clin. Sci. (Lond)."},{"key":"B83","first-page":"101","article-title":"Hypertriglyceridemia-induced acute pancreatitis: progress on disease mechanisms and treatment modalities","volume":"27","author":"Guo","year":"2019","journal-title":"Discov. Medicine"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/j.jacl.2024.04.086","article-title":"Study design of a phase 3 randomized controlled trial evaluating the efficacy and safety of pegozafermin in patients with severe hypertriglyceridemia","volume":"18","author":"Hartsfield","year":"2024","journal-title":"J. Clin. Lipidol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.2169\/internalmedicine.6574-20","article-title":"Impact of pemafibrate in patients with hypertriglyceridemia and metabolic dysfunction-associated fatty liver disease pathologically diagnosed with non-alcoholic steatohepatitis: a retrospective, single-arm study","volume":"60","author":"Hatanaka","year":"","journal-title":"Intern. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/jgh3.12650","article-title":"Effect of 48\u2010week pemafibrate on non\u2010alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan\u2010aspartate aminotransferase score","volume":"5","author":"Hatanaka","year":"","journal-title":"JGH Open"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e141513","DOI":"10.1172\/JCI141513","article-title":"Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223\u2013enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis","volume":"131","author":"He","year":"2021","journal-title":"J. Clin. Invest."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1872-034X.2008.00382.x","article-title":"Liver X receptor in cooperation with SREBP\u20101c is a major lipid synthesis regulator in nonalcoholic fatty liver disease","volume":"38","author":"Higuchi","year":"2008","journal-title":"Hepatol. Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"42477","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis","volume":"7","author":"Honda","year":"2017","journal-title":"Sci. Rep."},{"key":"B90","doi-asserted-by":"publisher","first-page":"973823","DOI":"10.3389\/fendo.2022.973823","article-title":"Triglyceride: A mediator of the association between waist-to-height ratio and non-alcoholic fatty liver disease: A second analysis of a population-based study","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"B91","doi-asserted-by":"crossref","DOI":"10.1053\/j.sult.2016.08.003","article-title":"Hepatic steatosis: etiology, patterns, and quantification","volume-title":"Seminars in Ultrasound, CT and MRI","author":"Idilman","year":"2016"},{"key":"B92","doi-asserted-by":"publisher","first-page":"188","DOI":"10.33160\/yam.2020.08.009","article-title":"Pemafibrate dramatically ameliorated the values of liver function tests and fibrosis marker in patients with non-alcoholic fatty liver disease","volume":"63","author":"Ikeda","year":"2020","journal-title":"Yonago Acta Medica"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.3390\/diagnostics11122316","article-title":"Pemafibrate ameliorates liver dysfunction and fatty liver in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: A retrospective study with the outcome after a mid-term follow-up","volume":"11","author":"Ikeda","year":"2021","journal-title":"Diagnostics"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: A major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J. Hepatol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cmet.2020.06.008","article-title":"FGF21 signals to glutamatergic neurons in the ventromedial hypothalamus to suppress carbohydrate intake","volume":"32","author":"Jensen-Cody","year":"2020","journal-title":"Cell Metab."},{"key":"B96","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2023.05.008","article-title":"Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS)","volume":"375","author":"Jones","year":"2023","journal-title":"Atherosclerosis"},{"key":"B97","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1161\/01.atv.19.3.472","article-title":"Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3","volume":"19","author":"Jong","year":"1999","journal-title":"Arteriosclerosis, Thrombosis, Vascular Biology"},{"key":"B98","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.cmet.2012.03.005","article-title":"Diacylglycerol activation of protein kinase C\u03b5 and hepatic insulin resistance","volume":"15","author":"Jornayvaz","year":"2012","journal-title":"Cell Metab."},{"key":"B100","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jacl.2022.01.001","article-title":"Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment","volume":"16","author":"Kallend","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1038\/s41598-022-06542-8","article-title":"Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy","volume":"12","author":"Kanno","year":"2022","journal-title":"Sci. Rep."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.amjcard.2016.02.011","article-title":"A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia","volume":"117","author":"Karlson","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jacl.2022.06.005","article-title":"Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia","volume":"16","author":"Karwatowska-Prokopczuk","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin. Res. Cardiol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1093\/eurheartj\/ehac544.3087","article-title":"An in vivo CRISPR base editing therapy to inactivate ANGPTL3: Nomination of a development candidate for VERVE-201","volume":"43","author":"Khera","year":"2022","journal-title":"Eur. Heart J."},{"key":"B106","doi-asserted-by":"publisher","first-page":"5121574","DOI":"10.1155\/2019\/5121574","article-title":"The triglyceride and glucose index is a predictor of incident nonalcoholic fatty liver disease: a population-based cohort study","volume":"2019","author":"Kitae","year":"2019","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","article-title":"A dozen years of discovery: insights into the physiology and pharmacology of FGF21","volume":"29","author":"Kliewer","year":"2019","journal-title":"Cell Metab."},{"key":"B108","volume-title":"Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study","author":"Kobyliak","year":"2018"},{"key":"B109","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3350\/cmh.2013.19.3.210","article-title":"Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis","volume":"19","author":"Koo","year":"2013","journal-title":"Clin. Mol. Hepatol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/CPAA.S345072","article-title":"Angiopoietin-like protein 3 (ANGPTL3) inhibitors in the management of refractory hypercholesterolemia","volume":"14","author":"Kosmas","year":"2022","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"B111","doi-asserted-by":"publisher","first-page":"470","DOI":"10.4254\/wjh.v5.i9.470","article-title":"Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease","volume":"5","author":"Kostapanos","year":"2013","journal-title":"World J. Hepatol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1210\/en.2005-0476","article-title":"Transgenic angiopoietin-like (angptl) 4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism","volume":"146","author":"Ko\u0308ster","year":"2005","journal-title":"Endocrinology"},{"key":"B113","doi-asserted-by":"publisher","first-page":"609465","DOI":"10.3389\/fphys.2021.609465","article-title":"Characterization of the CDAA diet-induced non-alcoholic steatohepatitis model: Sex-specific differences in inflammation, fibrosis, and cholesterol metabolism in middle-aged mice","volume":"12","author":"Kucsera","year":"2021","journal-title":"Front. Physiol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.clinbiochem.2014.03.008","article-title":"Plasma proprotein convertase subtilisin\u2013kexin type 9 is predominantly related to intermediate density lipoproteins","volume":"47","author":"Kwakernaak","year":"2014","journal-title":"Clin. Biochem."},{"key":"B115","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1194\/jlr.M400396-JLR200","article-title":"Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells","volume":"46","author":"Lalanne","year":"2005","journal-title":"J. Lipid Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"9037","DOI":"10.1074\/jbc.RA119.008094","article-title":"Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice","volume":"294","author":"Lebeau","year":"","journal-title":"J. Biol. Chem."},{"key":"B118","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jhepr.2019.10.009","article-title":"Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice","volume":"1","author":"Lebeau","year":"","journal-title":"Jhep Rep."},{"key":"B119","doi-asserted-by":"publisher","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study","volume":"116","author":"Lee","year":"2021","journal-title":"J. Am. Coll. Gastroenterol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/s0735-1097(23)01559-0","article-title":"Preclinical data supporting potential efficacy of VERVE-201-an investigational crispr base editing medicine targeting ANGPTL3-in primary human cells, mice, and non-human primates","volume":"81","author":"Lee","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/hep.28697","article-title":"Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients","volume":"65","author":"Leung","year":"2017","journal-title":"Hepatology"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1161\/ATVBAHA.114.304584","article-title":"Roles of acyl-CoA: diacylglycerol acyltransferases 1 and 2 in triacylglycerol synthesis and secretion in primary hepatocytes","volume":"35","author":"Li","year":"2015","journal-title":"Arteriosclerosis, Thrombosis, Vascular Biology"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1161\/ATVBAHA.107.151894","article-title":"Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL-and HL-dependent hepatic cholesterol uptake","volume":"27","author":"Lichtenstein","year":"2007","journal-title":"Arteriosclerosis, Thrombosis, Vascular Biology"},{"key":"B124","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jacl.2022.06.011","article-title":"Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy","volume":"16","author":"Lightbourne","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3892\/br.2017.890","article-title":"Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues","volume":"6","author":"Lin","year":"2017","journal-title":"Biomed. Rep."},{"key":"B126","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1073\/pnas.0630588100","article-title":"Triglyceride accumulation protects against fatty acid-induced lipotoxicity","volume":"100","author":"Listenberger","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B127","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/cvr\/cvab076","article-title":"Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis","volume":"118","author":"Liu","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1007\/s12325-021-01690-1","article-title":"Perspectives on precision medicine approaches to NAFLD diagnosis and management","volume":"38","author":"Lonardo","year":"2021","journal-title":"Adv. Ther."},{"key":"B129","first-page":"1266a","article-title":"BIO89-100, a novel glycopegylated FGF21 analogue, demonstrates robust reduction in serum lipids and long half-life in a phase 1 randomized, controlled single ascending dose trial in healthy subjects","volume":"70","author":"Loomba","year":"2019","journal-title":"Hepatology"},{"key":"B130","doi-asserted-by":"publisher","first-page":"S730","DOI":"10.1016\/s0168-8278(22)01781-0","article-title":"Pegozafermin improved liver histology, liver-related non-invasive tests (NITs) and metabolic profiles in an open-label cohort of a phase 1b\/2a study in subjects with non-alcoholic steatohepatitis (NASH)","volume":"77","author":"Loomba","year":"2022","journal-title":"J. Hepatol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","article-title":"Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study","volume":"8","author":"Loomba","year":"","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"","journal-title":"N. Engl. J. Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(25)00979-1","article-title":"Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"406","author":"Loomba","year":"2025","journal-title":"Lancet"},{"key":"B134","doi-asserted-by":"publisher","first-page":"104413","DOI":"10.1016\/j.phrs.2019.104413","article-title":"A new dawn for managing dyslipidemias: The era of rna-based therapies","volume":"150","author":"Macchi","year":"2019","journal-title":"Pharmacol. Res."},{"key":"B135","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/cvr\/cvae136","article-title":"Advances in nucleic acid-targeted therapies for cardiovascular disease prevention","volume":"120","author":"Makhmudova","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"B137","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n\u2212 3 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B138","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1742-4658.2010.07972.x","article-title":"Interruption of triacylglycerol synthesis in the endoplasmic reticulum is the initiating event for saturated fatty acid\u2010induced lipotoxicity in liver cells","volume":"278","author":"Mantzaris","year":"2011","journal-title":"FEBS J."},{"key":"B139","article-title":"Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study","volume-title":"Circulation","author":"Marston","year":""},{"key":"B140","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41569-021-00613-5","article-title":"Apolipoproteins in vascular biology and atherosclerotic disease","volume":"19","author":"Mehta","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"56","DOI":"10.12688\/f1000research.21918.1","article-title":"Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis","volume":"9","author":"M\u00e9ndez-S\u00e1nchez","year":"2020","journal-title":"F1000Research"},{"key":"B142","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/17512433.2022.2132229","article-title":"The role of PCSK9 in NAFLD\/NASH and therapeutic implications of PCSK9 inhibition","volume":"15","author":"Momtazi-Borojeni","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6823-12-2","article-title":"The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis","volume":"12","author":"Murad","year":"2012","journal-title":"BMC Endocrine Disorders"},{"key":"B145","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3390\/cells11040720","article-title":"Selective PPAR\u03b1 modulator pemafibrate and sodium-glucose cotransporter 2 inhibitor tofogliflozin combination treatment improved histopathology in experimental mice model of non-alcoholic steatohepatitis","volume":"11","author":"Murakami","year":"2022","journal-title":"Cells"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator\u2010activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non\u2010alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Alimentary Pharmacol. Ther."},{"key":"B147","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"J. Clin. Gastroenterol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander\u2010Tetri","year":"2010","journal-title":"Hepatology"},{"key":"B149","doi-asserted-by":"publisher","first-page":"51664","DOI":"10.1074\/jbc.M309377200","article-title":"Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene","volume":"278","author":"Newberry","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B150","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"Jama"},{"key":"B151","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circulation Res."},{"key":"B152","doi-asserted-by":"publisher","first-page":"e0195147","DOI":"10.1371\/journal.pone.0195147","article-title":"Cigarette smoking is a risk factor for the onset of fatty liver disease in nondrinkers: a longitudinal cohort study","volume":"13","author":"Okamoto","year":"2018","journal-title":"PloS One"},{"key":"B153","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","article-title":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study","volume":"16","author":"Oral","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.jacl.2018.08.003","article-title":"Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study","volume":"12","author":"Oscarsson","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1161\/01.ATV.0000133684.77013.88","article-title":"Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9","volume":"24","author":"Ouguerram","year":"2004","journal-title":"Arteriosclerosis, Thrombosis, Vascular Biology"},{"key":"B156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-022-01631-z","article-title":"Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia","volume":"21","author":"Paragh","year":"2022","journal-title":"Lipids Health Dis."},{"key":"B157","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/bcp.14943","article-title":"Statin liver safety in non\u2010alcoholic fatty liver disease: A systematic review and metanalysis","volume":"88","author":"Pastori","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1172\/JCI34275","article-title":"Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice","volume":"118","author":"Postic","year":"2008","journal-title":"J. Clin. Invest."},{"key":"B159","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jacl.2023.04.007","article-title":"APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia","volume":"17","author":"Prohaska","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/MOL.0000000000000502","article-title":"Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism","volume":"29","author":"Ramms","year":"2018","journal-title":"Curr. Opinion Lipidol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1016\/j.jacc.2021.04.059","article-title":"Triglycerides and residual atherosclerotic risk","volume":"77","author":"Raposeiras-Roubin","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1515\/abm-2018-0026","article-title":"Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Rattanachaisit","year":"2018","journal-title":"Asian Biomed."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/s0735-1097(24)03663-5","article-title":"Solbinsiran, a galnac-conjugated sirna targeting angptl3, reduces atherogenic lipoproteins in individuals with mixed dyslipidaemia in a durable and dosedependent manner","volume":"83","author":"Ray","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/S0140-6736(25)00507-0","article-title":"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Ray","year":"2025","journal-title":"Lancet"},{"key":"B166","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genetics"},{"key":"B169","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B170","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat. Med."},{"key":"B171","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B172","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1016\/s0618-8278(19)30274-9","article-title":"BIO89-100, a novel PEG-FGF21 analogue, is efficacious following weekly and every 2-week subcutaneous dosing in spontaneous diabetic cynomolgus monkeys","volume":"70","author":"Rosenstock","year":"2019","journal-title":"J. Hepatol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1124\/jpet.123.001618","article-title":"The novel GlycoPEGylated FGF21 analog pegozafermin activates human FGF receptors and improves metabolic and liver outcomes in diabetic monkeys and healthy human volunteers","volume":"387","author":"Rosenstock","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B174","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1210\/jc.2019-01338","article-title":"Primary prevention of ASCVD and T2DM in patients at metabolic risk: an Endocrine Society clinical practice guideline","volume":"104","author":"Rosenzweig","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B175","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jare.2020.05.020","article-title":"The FGF-21 genetic variants rs838133 and rs838145 are associated with high salt intake in the Emirati population","volume":"24","author":"Saber-Ayad","year":"2020","journal-title":"J. Adv. Res."},{"key":"B176","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.plipres.2014.07.002","article-title":"Recent advances in pharmacotherapy for hypertriglyceridemia","volume":"56","author":"Sahebkar","year":"2014","journal-title":"Prog. Lipid Res."},{"key":"B177","doi-asserted-by":"publisher","first-page":"101127","DOI":"10.1016\/j.plipres.2021.101127","article-title":"A comprehensive review on the lipid and pleiotropic effects of pitavastatin","volume":"84","author":"Sahebkar","year":"2021","journal-title":"Prog. Lipid Res."},{"key":"B178","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/j.gastro.2014.04.046","article-title":"No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial","volume":"147","author":"Sanyal","year":"2014","journal-title":"Gastroenterology"},{"key":"B179","doi-asserted-by":"publisher","first-page":"7818","DOI":"10.1038\/s41598-020-64902-8","article-title":"Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content","volume":"10","author":"Sasaki","year":"2020","journal-title":"Sci. Rep."},{"key":"B180","doi-asserted-by":"publisher","first-page":"14372","DOI":"10.1073\/pnas.1611243113","article-title":"KLB is associated with alcohol drinking, and its gene product \u03b2-Klotho is necessary for FGF21 regulation of alcohol preference","volume":"113","author":"Schumann","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B181","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.numecd.2020.11.009","article-title":"Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience","volume":"31","author":"Scicali","year":"2021","journal-title":"Nutr. Metabolism Cardiovasc. Dis."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/hepr.13571","article-title":"Effect of pemafibrate on fatty acid levels and liver enzymes in non\u2010alcoholic fatty liver disease patients with dyslipidemia: a single\u2010arm, pilot study","volume":"50","author":"Seko","year":"2020","journal-title":"Hepatol. Res."},{"key":"B183","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12933-022-01524-6","article-title":"Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases","volume":"21","author":"Seo","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2174\/1570161118666201015152921","article-title":"Prevalence, diagnosis, and treatment with 3 different statins of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis in military personnel. Do genetics play a role?","volume":"19","author":"Sfikas","year":"2021","journal-title":"Curr. Vasc. Pharmacol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.4254\/wjh.v12.i12.1258","article-title":"Effects of proprotein convertase subtilisin\/kexin type-9 inhibitors on fatty liver","volume":"12","author":"Shafiq","year":"2020","journal-title":"World J. Hepatol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"270","DOI":"10.5114\/ceh.2020.99528","article-title":"Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease","volume":"6","author":"Shinozaki","year":"2020","journal-title":"Clin. Exper. Hepatol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1093\/eurheartj\/ehad261","article-title":"Inverse association between apolipoprotein C-II and cardiovascular mortality: role of lipoprotein lipase activity modulation","volume":"44","author":"Silbernagel","year":"2023","journal-title":"Eur. Heart J."},{"key":"B188","doi-asserted-by":"publisher","first-page":"m3109","DOI":"10.1136\/bmj.m3109","article-title":"Management of hypertriglyceridemia","volume":"371","author":"Simha","year":"2020","journal-title":"Bmj"},{"key":"B189","doi-asserted-by":"publisher","first-page":"10659","DOI":"10.1074\/jbc.M116.719955","article-title":"Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins","volume":"291","author":"Smagris","year":"2016","journal-title":"J. Biol. Chem."},{"key":"B190","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.cmet.2017.04.009","article-title":"FGF21 is a sugar-induced hormone associated with sweet intake and preference in humans","volume":"25","author":"S\u00f8berg","year":"2017","journal-title":"Cell Metab."},{"key":"B191","doi-asserted-by":"publisher","first-page":"357","DOI":"10.5114\/aoms\/186191","article-title":"Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders","volume":"20","author":"Solnica","year":"2024","journal-title":"Archives Med. Sci."},{"key":"B192","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/jcm12010168","article-title":"Evinacumab, an ANGPTL3 inhibitor, in the treatment of dyslipidemia","volume":"12","author":"Sosnowska","year":"2022","journal-title":"J. Clin. Med."},{"key":"B193","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.dld.2007.10.003","article-title":"Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease","volume":"40","author":"Spadaro","year":"2008","journal-title":"Dig. Liver Dis."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/14656566.2023.2206015","article-title":"Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors","volume":"24","author":"Spagnuolo","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"B195","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jnutbio.2018.03.025","article-title":"Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids","volume":"58","author":"Spahis","year":"2018","journal-title":"J. Nutrit. Biochem."},{"key":"B196","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3109\/10409231003667500","article-title":"Genetic control of de novo lipogenesis: role in diet-induced obesity","volume":"45","author":"Strable","year":"2010","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B198","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40265-025-02166-0","article-title":"Olezarsen: first approval","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"key":"B199","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/jdi.12621","article-title":"Selective peroxisome proliferator\u2010activated receptor\u2010\u03b1 modulator K\u2010877 efficiently activates the peroxisome proliferator\u2010activated receptor\u2010\u03b1 pathway and improves lipid metabolism in mice","volume":"8","author":"Takei","year":"2017","journal-title":"J. Diabetes Invest."},{"key":"B200","doi-asserted-by":"publisher","first-page":"e148559","DOI":"10.1172\/JCI148559","article-title":"Addressing dyslipidemic risk beyond LDL-cholesterol","volume":"132","author":"Tall","year":"2022","journal-title":"J. Clin. Invest."},{"key":"B201","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.pharmthera.2017.05.011","article-title":"Targeting nuclear receptors for the treatment of fatty liver disease","volume":"179","author":"Tanaka","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"B202","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1194\/jlr.M300508-JLR200","article-title":"Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity","volume":"45","author":"Tanoli","year":"2004","journal-title":"J. Lipid Res."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur. Heart J."},{"key":"B204","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11883-016-0614-1","article-title":"Why is apolipoprotein CIII emerging as a novel therapeutic target to reduce the burden of cardiovascular disease?","volume":"18","author":"Taskinen","year":"2016","journal-title":"Curr. Atherosclerosis Rep."},{"key":"B205","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11883-019-0791-9","article-title":"Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD","volume":"21","author":"Taskinen","year":"2019","journal-title":"Curr. Atherosclerosis Rep."},{"key":"B206","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nature09270","article-title":"Biological, clinical and population relevance of 95 loci for blood lipids","volume":"466","author":"Teslovich","year":"2010","journal-title":"Nature"},{"key":"B207","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/pds.4020","article-title":"Statin use and the risk of developing diabetes: a network meta\u2010analysis","volume":"25","author":"Thakker","year":"2016","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"B208","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.2174\/1381612824666181010123127","article-title":"The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors","volume":"24","author":"Theocharidou","year":"2018","journal-title":"Curr. Pharmaceutical Design"},{"key":"B209","doi-asserted-by":"publisher","first-page":"601290","DOI":"10.3389\/fendo.2020.601290","article-title":"FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases","volume":"11","author":"Tillman","year":"2020","journal-title":"Front. Endocrinol."},{"key":"B210","first-page":"256","volume-title":"The year in cardiovascular medicine 2022: the top 10 papers in dyslipidaemias","author":"Tokgozoglu","year":"2023"},{"key":"B211","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12944-016-0197-4","article-title":"Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo","volume":"15","author":"Toth","year":"2016","journal-title":"Lipids Health Dis."},{"key":"B212","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.amjcard.2017.10.028","article-title":"Effect of evolocumab on lipoprotein particles","volume":"121","author":"Toth","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4254\/wjh.v14.i1.119","article-title":"Is there a role of lipid-lowering therapies in the management of fatty liver disease?","volume":"14","author":"Tzanaki","year":"2022","journal-title":"World J. Hepatol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1210\/jc.2016-3903","article-title":"A novel APOC2 missense mutation causing apolipoprotein C-II deficiency with severe triglyceridemia and pancreatitis","volume":"102","author":"Ueda","year":"2017","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"B215","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"B216","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MOL.0b013e32833af4c1","article-title":"Apolipoprotein B synthesis inhibition: results from clinical trials","volume":"21","author":"Visser","year":"2010","journal-title":"Curr. Opinion Lipidol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.cmet.2015.12.003","article-title":"FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver","volume":"23","author":"von Holstein-Rathlou","year":"2016","journal-title":"Cell Metab."},{"key":"B218","doi-asserted-by":"publisher","first-page":"e76538","DOI":"10.1371\/journal.pone.0076538","article-title":"Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis","volume":"8","author":"Wang","year":"2013","journal-title":"PloS One"},{"key":"B219","doi-asserted-by":"publisher","first-page":"A178","DOI":"10.1016\/j.jacc.2026.02.443","article-title":"26-A-10903-ACC apolipoprotein C-III (APOC3) inhibition in patients with versus without baseline fibrate use","volume":"87","author":"Wang","year":"2026","journal-title":"J. Am. Coll. Cardiol."},{"key":"B220","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","article-title":"RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts","volume":"29","author":"Watts","year":"2023","journal-title":"Nat. Med."},{"key":"B221","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B222","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/MOL.0000000000000072","article-title":"Hypobetalipoproteinemia and abetalipoproteinemia","volume":"25","author":"Welty","year":"2014","journal-title":"Curr. Opinion Lipidol."},{"key":"B223","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.2337\/db07-0156","article-title":"Genes involved in fatty acid partitioning and binding, lipolysis, monocyte\/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects","volume":"56","author":"Westerbacka","year":"2007","journal-title":"Diabetes"},{"key":"B224","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B225","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/cells10030597","article-title":"Apolipoprotein mimetic peptides: potential new therapies for cardiovascular diseases","volume":"10","author":"Wolska","year":"2021","journal-title":"Cells"},{"key":"B226","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S2468-1253(25)00128-1","article-title":"Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2\u2013F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study","volume":"10","author":"Wong","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B227","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"B228","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1210\/jc.2013-3619","article-title":"Autoimmune severe hypertriglyceridemia induced by anti-apolipoprotein C-II antibody","volume":"99","author":"Yamamoto","year":"2014","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"B229","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"B230","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jjcc.2022.07.008","article-title":"Eicosapentaenoic acid for cardiovascular events reduction-systematic review and network meta-analysis of randomized controlled trials","volume":"80","author":"Yokoyama","year":"2022","journal-title":"J. Cardiol."},{"key":"B231","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/hep.20783","article-title":"Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice","volume":"42","author":"Yu","year":"2005","journal-title":"Hepatology"},{"key":"B232","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10654-022-00868-3","article-title":"Lifestyle and metabolic factors for nonalcoholic fatty liver disease: Mendelian randomization study","volume":"37","author":"Yuan","year":"2022","journal-title":"Eur. Journal Epidemiol."},{"key":"B233","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte\u2010specific low\u2010density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"B234","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1161\/CIRCULATIONAHA.109.897330","article-title":"Adipocyte modulation of high-density lipoprotein cholesterol","volume":"121","author":"Zhang","year":"2010","journal-title":"Circulation"},{"key":"B235","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-018-0913-3","article-title":"A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease","volume":"17","author":"Zheng","year":"2018","journal-title":"Lipids Health Dis."},{"key":"B236","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1016\/j.jacl.2023.12.001","article-title":"Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3","volume":"18","author":"Zimerman","year":"2023","journal-title":"J. Clin. Lipidol."}],"updated-by":[{"DOI":"10.3389\/fphar.2026.1943610","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1789019\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:30:29Z","timestamp":1785227429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1789019\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":237,"alternative-id":["10.3389\/fphar.2026.1789019"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1789019","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"article-number":"1789019"}}